uniQure QURE
NASDAQ QURE
$44.50 -0.36 (-0.80%)
As of: Sep 4, 2026 · 3:59 PM EDT

uniQure (QURE) Cash from Financing Activities (2016 - 2026)

uniQure (QURE) posted quarterly Cash from Financing Activities of $249.1 million for Q2 2026, up 566072.73% year-over-year from N/an in Q2 2025, and up 45193.82% quarter-over-quarter from $550000.0 in Q1 2026.

Analysis

uniQure (QURE) Cash from Financing Activities (2016 - 2026) Analysis & Trends

uniQure's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $249.1 million for Q2 2026.

  • In Q2 2026, Cash from Financing Activities rose 566072.73% year-over-year to $249.1 million; the TTM figure through Jun 2026 stood at $584.4 million (up 2659.23% YoY), while the FY2025 annual figure was $415.4 million, up 798.31% from the prior year.
  • Cash from Financing Activities for Q2 2026 stood at $249.1 million, up from $550000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $370.1 million in Q2 2023, with the low at -$53.0 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $393000.0 (2022), against an average of $60.6 million.
  • The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 638067.24% in 2023, then plunged 14267.39% in 2024.
  • uniQure's Cash from Financing Activities stood at $601000.0 in 2022, then tumbled by 92.35% to $46000.0 in 2023, then slumped by 14267.39% to -$6.5 million in 2024, then jumped by 137.58% to $2.4 million in 2025, then surged by 10072.15% to $249.1 million in 2026.
  • Business Quant data shows QURE's Cash from Financing Activities at $249.1 million in Q2 2026, $550000.0 in Q1 2026, and $2.4 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 uniQure 2.95 Bn 2.95 Bn 5.49 Mn 249.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 249.12 Mn
Mar 31, 2026 550,000.00
Dec 31, 2025 2.45 Mn
Sep 30, 2025 332.24 Mn
Jun 30, 2025 44,000.00
Mar 31, 2025 80.67 Mn
Dec 31, 2024 -6.52 Mn
Sep 30, 2024 -53.02 Mn
Dec 31, 2023 46,000.00
Sep 30, 2023 -7.59 Mn
Jun 30, 2023 370.14 Mn
Mar 31, 2023 131,000.00
Dec 31, 2022 601,000.00
Sep 30, 2022 301,000.00
Jun 30, 2022 58,000.00
Mar 31, 2022 485,000.00
Dec 31, 2021 29.89 Mn
Sep 30, 2021 -164,000.00
Jun 30, 2021 2.51 Mn
Mar 31, 2021 62.62 Mn